Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
32.24
+0.29 (0.91%)
Nov 21, 2024, 3:34 PM EST - Market open
Edgewise Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
88
Market Cap
3.05B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bausch Health Companies | 9.47B |
Amedisys | 2.32B |
Veracyte | 425.33M |
Merus | 35.93M |
Agios Pharmaceuticals | 32.87M |
Verona Pharma | 5.62M |
EWTX News
- 14 days ago - Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Business Wire
- 7 weeks ago - Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society - Business Wire
- 7 weeks ago - Analysts Think There's Still Time To Get In On Edgewise - Benzinga
- 2 months ago - Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge - Benzinga
- 2 months ago - Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment - Benzinga
- 2 months ago - Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) - Business Wire
- 2 months ago - Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time - Business Wire
- 3 months ago - Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - Business Wire